Kindred Biosciences, Inc. (NASDAQ:KIN) is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.3 per share.
Looking ahead, the full year loss are expected at $ 0.53 per share on the revenues of $ 41.24 million.
Previous Quarter Performance
Kindred Biosciences, Inc. unwinded income for the second quarter of $ 0.60 per share, from the revenue of $ 39.57 million. The consensus estimates are $ 10.54 million in revenue The top line results outshined analysts by $ 29.03 million or 275.43 percent.
Stock Performance
On Friday, shares of Kindred Biosciences, Inc. has traded high as $ 3.86 and has cracked $ 3.60 on the downward trend, reaching $ 3.78 with volume of 193.80 thousand shares.
According to the previous trading day, closing price of $ 3.78, representing a 23.79 % increase from the 52 week low of $ 3.11 and a 67.73 % decrease over the 52 week high of $ 11.93.
The company has a market capital of $ 137.56 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Kindred Biosciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.kindredbio.com
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
